We then checked the effect of these RXRA ligands on the BCR-ABL signaling pathways (p-CRKL as a marker of proliferation, p-AKT as a marker of survival, and p-STAT5 as a marker of quiescence) in CML cell lines and primary cells. Here, CRKL is linked to chronic myelogenous leukemia, BCR-ABL1 positive.